ERBB2 L755S

erbb2 l755s是第一个功能分类的erbb2变体（Bose等人2013年）。这一突变并没有被证明是一个激活的突变，不像其他许多被质疑的突变。这一突变也显示了对MCF10A细胞系中的酪氨酸激酶抑制剂拉帕替尼的耐药性。
ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.